A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae

Inclusion Criteria:

- The subject is an adult male or female at least 18 years of age at the time of
signing informed consent who meets one of the following criteria:

1. A non-pregnant, non-lactating female of childbearing potential who 1) is
sexually inactive by abstinence, 2) has a sole male partner who has been
sterilized, or 3) uses a contraceptive method with a failure rate of <1% through
the Test-of-Cure Visit. Females of childbearing potential must not become
pregnant during the study.

2. A female of non-childbearing potential, which includes the following: Females
who are surgically sterile with a documented hysterectomy and/or bilateral
oophorectomy; Females with documented tubal ligation. If the procedure was done
hysteroscopically, the effectiveness of tubal occlusion must have been
documented by hysterosalpingogram after the procedure (typically 3 months after
the procedure); Females who are post-menopausal, defined as amenorrhoeic for
greater than 1 year. For women whose menopausal status is in doubt, documented
previous confirmatory blood samples with follicle-stimulating hormone >40 milli
international units (mIU)/millilitre (mL) and estradiol <40 picograms (pg)/mL
(<140 picomoles [pmol]/litre [L]) will need to be confirmed, or they will be
required to use one of the acceptable contraception methods. Note: For the
purposes of these criteria, "documented" includes information obtained via a
verbal interview with the subject or from the subject's medical records.

- There is clinical suspicion that the subject has a urogenital gonococcal infection
(e.g., prior culture, nucleic acid amplification test [NAAT] or Gram stain
presumptive or positive for the presence of N. gonorrhoeae, or sexual contact with a
partner diagnosed with gonorrhea within the past 14 days, as reported by the
subject). Note: All subjects will be tested for N. gonorrhoeae, but these results
will not be used to determine subject eligibility for enrollment in the study.

- The subject has provided written, dated, informed consent and is willing and able to
comply with the study protocol.

Exclusion Criteria:

- The subject is pregnant or nursing.

- The subject is a hysterectomized female without a cervix.

- The subject is a male with a current diagnosis of epididymitis or orchitis at the
time of the Baseline Visit.

- The subject has a body mass index >=40.0 kilograms (kg)/square meter (m^2).

- The subject has a serious underlying disease that could be imminently life
threatening, or the subject is unlikely to survive for the duration of the study
period.

- The subject has a medical condition or requires medication that may be aggravated by
inhibition of acetylcholinesterase, such as: Poorly controlled asthma or chronic
obstructive pulmonary disease at baseline and, in the opinion of the investigator, is
not stable on current therapy; Acute severe pain, uncontrolled with conventional
medical management; Active peptic ulcer disease; Parkinson's disease; Myasthenia
gravis; A history of seizure disorder requiring medications for control. This does
not include a history of childhood febrile seizures; Any evidence of mechanical
obstruction of the urinary or digestive tracks.

- The subject has had any past history or current diagnosis of Clostridium difficile
infection at the time of the Baseline Visit.

- The subject, in the judgment of the investigator, would not be able or willing to
comply with the protocol or complete study follow-up.

- The subject has a history of sensitivity to the study medication, or components
thereof, or a history of a drug or other allergy that, in the opinion of the
investigator or medical monitor, contraindicates their participation.

- The subject has a PR interval <120 or >220 milliseconds (msec). Note: Subjects
without an evaluable PR interval (e.g., stable atrial fibrillation) are not eligible
for this study.

- The subject has a corrected QT (QTc) >450 msec or a QTc >480 msec for subjects with
bundle branch block. Note: The QTc is the QT interval corrected for heart rate
according to either Bazett formula (QTcB), Fridericia formula (QTcF), machine, or
manual overread.

- The subject has QRS duration <70 or >120 msec.

- The subject has pre-existing Grade II atrioventricular block or higher or a history
of significant vasovagal and/or syncopal episodes or episodes of symptomatic
bradycardia.

- The subject has a current or chronic history of liver disease (with the exception of
Gilbert's syndrome), including symptomatic viral hepatitis and moderate to severe
liver insufficiency (Child Pugh class B or C).

- The subject has been previously enrolled in this study or has previously been treated
with GSK2140944.

- The subject has participated in a clinical trial and has received an investigational
product within 30 days or 5 half-lives, whichever is longer.

- The subject has the following gonococcal infections: Suspected or confirmed pelvic
inflammatory disease; Suspected or confirmed gonococcal arthritis; Other evidence of
disseminated gonococcal infection.

- The subject has received treatment with a systemic or intravaginal antibacterial
within 14 days of study entry.

- Subject is taking a medication that has a known risk of torsades de pointes.